AI assistant
Sending…
Spyre Therapeutics, Inc. — Director's Dealing 2017
Jul 10, 2017
32226_dirs_2017-07-10_a0b15cde-c9fa-4a61-b5fb-a5ee4fb6d3da.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2017-07-10
Reporting Person: Wooldridge James (Chief Medical Officer)
More from Spyre Therapeutics, Inc.
Regulatory Filings
2026
Jun 1
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 5
Interim / Quarterly Report
2026
May 5
Regulatory Filings
2026
Apr 16
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 13
Proxy Solicitation & Information Statement
2026
Apr 10
Major Shareholding Notification
2026
Mar 27